You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,770,535


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,770,535
Title:Scaffolds for cell collection or elimination
Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
Inventor(s): Mooney; David J. (Sudbury, MA), Ali; Omar Abdel-Rahman (Cambridge, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:12/665,761
Patent Claims:1. A method of removing or eliminating a cancer cell from a mammalian subject, comprising a) administering to the subject, a device comprising a scaffold composition and a bioactive composition, said bioactive composition being incorporated into or conjugated onto said scaffold composition, wherein said scaffold composition comprises a polymer matrix and pores, and wherein the bioactive composition comprises a cell attractant and a cell death-inducing agent, wherein said scaffold composition does not comprise cells prior to said administering step, b) exposing said cancer cell to said cell attractant, thereby recruiting the cancer cell to the scaffold composition, c) capturing said cancer cell within said scaffold composition, thereby sequestering said cancer cell from the host environment, and d) killing the sequestered cancer cell within said scaffold composition by exposure to the scaffold composition or to the cell death-inducing agent, wherein the sequestered cancer cell is killed without removing the device from the subject, thereby removing or eliminating the cancer cell from the subject.

2. The method of claim 1, wherein the cell attractant disseminates from said scaffold composition.

3. The method of claim 1, wherein said device is administered orally, systemically, by lumbar puncture to access cerebral spinal fluid, subcutaneously, transcutaneously, as an arterial stent, or surgically.

4. The method of claim 1, further comprising the step of collecting said device from the subject.

5. The method of claim 1, wherein the bioactive composition comprises an antigen or an adhesive compound.

6. The method of claim 1, wherein the cancer cell comprises a metastatic cancer cell.

7. The method of claim 1, wherein the cancer cell displays a surface antigen.

8. The method of claim 1, wherein the cell attractant comprises a cytokine or a chemokine.

9. The method of claim 8, wherein the cytokine or chemokine attracts metastatic cancer cells, immune cells, or both metastatic cancer cells and immune cells.

10. The method of claim 1, wherein the bioactive composition comprises an inhibitor of chemokine receptor activity.

11. The method of claim 10, wherein the inhibitor comprises AMD3100, T22, TN14003, T140, TC14012, 4F-bTE, BX-471, Met-CCL5, TAK779, or TAK220.

12. The method of claim 1, wherein the bioactive composition comprises an anti-metastatic compound.

13. The method of claim 1, wherein the device adheres to a surface protein on the cancer cell, wherein the surface protein is unique to cancer cells.

14. The method of claim 1, wherein the polymer comprises poly(lactide-co-glycolide)(PLGA).

15. The method of claim 1, wherein the size of the pores is less than about 10 nm, in the range of 100 nm to 2 .mu.M, or greater than about 20 .mu.M in diameter.

16. The method of claim 15, wherein the size of the pores is about 400 .mu.M to 500 .mu.M in diameter.

17. The method of claim 1, wherein the cell death-inducing agent comprises a compound that prevents or arrests cell division, an engineered virus, a humanized monoclonal antibody to activate the immune system, a pro-apoptotic ligand, a radioactive isotope, a toxin, or a chemotherapeutic agent.

18. The method of claim 17, wherein the pro-apoptotic ligand comprises FasL, TNF, TRAIL, or a caspase activator.

19. The method of claim 17, wherein the radioactive isotope comprises Bismuth-213, Holmium-66, Iodine-125, Iodine-131, or Lutetium-177.

20. The method of claim 17, wherein the toxin comprises a hemotoxin, a necrotoxin, or a neurotoxin.

21. The method of claim 17, wherein the compound that prevents or arrests cell division comprises Dacarbazine, Fluorouracil, Fludarabine, Gemcitabine, Trastuzumab, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Cladribine/Leustatin, Mercaptopurine, Methotrexate, Mithramycin, Mitomycin, Mitoxanthrone, Navelbine, Nitrogen Mustard, Rituxan, Paclitaxel, Docetaxel, Topotecan, Velban, Vincristine, or Etoposide.

22. The method of claim 1, wherein the cell attractant comprises a multivalent acrylamide polymer linked to a sugar, a polylysine linked to a sugar, or an amino acid.

23. The method of claim 22, wherein the sugar comprises galactose, fructose, or ribose.

24. The method of claim 22, wherein the amino acid comprises aspartate, leucine, or serine.

25. The method of claim 1, wherein the device is administered by implanting into a tissue of the subject which is not blood tissue.

26. The method of claim 25, wherein the device is administered by implanting into a site selected from the group consisting of adipose tissue, gastrointestinal tract, lymphatic fluid, primary tumor site, and cerebral spinal fluid.

27. The method of claim 1, wherein the device is not collected from the subject.

Details for Patent 9,770,535

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2027-06-21
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2027-06-21
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2027-06-21
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2027-06-21
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2027-06-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.